ArticleCurrent drug delivery2026
Innovative Drug Delivery Strategies for Enhanced Treatment of Antimicrobial Resistance.
Article in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntimicrobial resistance (AMR) presents a major global health threat, driven by the overuse and misuse of antibiotics. Traditional drug delivery systems face significant limitations in effectively addressing this issue, including poor targeting, low bioavailability, and the development of resistance. Nanoparticle-based drug delivery systems (NDDS) have emerged as a novel approach to overcome these limitations and combat resistant bacteria by improving drug delivery and targeting. This review aims to evaluate the mechanisms of AMR and the effectiveness of nanoparticle- based drug delivery systems in combating resistant bacteria.
methodsThe methodology employed in this review involved a systematic search of peer-reviewed literature in databases such as PubMed, Google Scholar, Scopus, and Web of Science. The search strategy focused on identifying relevant articles using keywords and phrases such as "nanoparticle drug delivery systems," "antimicrobial resistance," "nanomedicine," "liposomes," "nanoemulsions," and "polymeric nanoparticles." The review included studies evaluating the mechanisms of antimicrobial resistance, the applications of NDDS, and their implications and advancements in combating AMR.
resultsNanoscale drug delivery vehicles and antibacterial nanoparticles have demonstrated significant potential as effective treatments for infections. Nanoparticles, with their small and controllable size, offer unique properties such as enhanced reactivity, a functionalizable structure, and a high surface area-to-volume ratio. NDDS, including liposomes, nanoemulsions, solid lipid nanoparticles, polymeric nanoparticles, and metal nanoparticles, have gained attention due to their ability to enhance drug bioavailability and targeting effectiveness.
conclusionNanoparticles present a promising strategy to combat AMR. Their capacity to bypass traditional resistance mechanisms and improve drug delivery underscores their potential in the development of effective antimicrobial therapies. Further research is essential to optimize nanoparticle formulations for clinical translation, ensuring their safety and efficacy in treating resistant bacterial infections. This review highlights the importance of integrating nanotechnology into antimicrobial strategies to address the growing challenge of AMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.